Last updated: 04/10/2025 05:42:20

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Request patient level data
GSK study ID
205232
See study documents
Clinicaltrials.gov ID
NCT02285777
EudraCT ID
2015-001030-16
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.
Trial description: This is extension of the V102_16 study (NCT02140762). V102_16E1 is designed to assess the effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6 month schedule, against the same panel of endemic US N. meningitidis serogroup B strains, as measured by enc-hSBA assay. The subjects who completed the parent V102_16 study will be invited at the time of their last study visit to participate in this extension study.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Percentages of subjects without bactericidal activity at 1:4 dilution against each US Neisseria meningitides (N. meningitidis) serogroup B strain at 1 month after the 3-dose vaccination series.

Timeframe: At Month 7 (1 month after the 3-dose vaccination series)

Secondary outcomes:

Percentages of subjects without bactericidal activity at 1:4 dilution against each US N. meningitidis serogroup B strain at 4 months after the 3-dose vaccination series.

Timeframe: At Month 10 (4 months after the 3-dose vaccination series)

Percentages of subjects without bactericidal activity at 1:8 dilution against each US N. meningitidis serogroup B strain at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentages of US N. meningitidis serogroup B strains killed at 1:4 and 1:8 dilutions at 1 and 4 months after the 3-dose vaccination series

Timeframe: At Month 6 (before the 3-dose vaccination series) and at Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentages of subjects with enc-hSBA ≥ 1:4 and enc-hSBA ≥1:8 at 1 and 4 months after the 3-dose vaccination series

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

HT-hSBA Geometric Mean Titers (GMTs) against the N. meningitidis serogroup B test strains

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains ≥ Lower Limit of Quantitation (LLQ) at 1 month after the 3-dose vaccination series.

Timeframe: At Month 7 (1 month after the 3-dose vaccination series)

Percentages of subjects with HT-hSBA titers against N. meningitidis serogroup B test strains ≥ LLQ at 4 months after the 3-dose vaccination series

Timeframe: At Month 10 (4 months after the 3-dose vaccination series)

Percentages of subjects with a two-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentages of subjects with a three-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At months 7 and 10 (1 and 4 months after 3-dose vaccination series)

Percentages of subjects with a four-fold rise in HT-hSBA titers against the N. meningitidis serogroup B test strains at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

HT-hSBA GMTs against N. meningitidis serogroups A, C, W and Y.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 1 month after the 3- dose vaccination series

Timeframe: At Month 7 (1 month after the 3-dose vaccination series)

Percentages of subjects with HT-hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 4 months after the 3-dose vaccination series

Timeframe: At Month 10 (4 months after the 3-dose vaccination series)

Percentage of subjects with two-fold rise in HT-hSBA titers against the N. meningitidis serogroups A, C,W and Y at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentage of subjects with three-fold rise in HT-hSBA titers against the N. meningitidis serogroups A, C, W and Y at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentage of subjects with four-fold rise in HT-hSBA titers against the N. meningitidis serogroups A, C, W and Y at 1 and 4 months after the 3-dose vaccination series.

Timeframe: At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)

Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroup B Test Strains≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at 1 Month After the 3-dose Vaccination Series

Timeframe: At Month 7 (1 month after the 3-dose vaccination series)

Percentages of Subjects With HT-hSBA Titers Against N. Meningitidis Serogroup B Test Strains ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 at 4 Months After the 3-dose Vaccination Series

Timeframe: At Month 10 (4 months after the 3-dose vaccination series)

Percentages of Subjects With HT-hSBA Titers Against the N. Meningitidis Serogroup A, C, W and Y ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥128 at 1 Month After the 3- Dose Vaccination Series

Timeframe: At Month 7 (1 month after the 3-dose vaccination series)

Percentages of Subjects With HT-hSBA Titers Against the N. Meningitidis Serogroup A, C, W and Y ≥8, ≥ 16, ≥ 32, ≥ 64, ≥128 at 4 Months After the 3-dose Vaccination Series

Timeframe: At Month 10 (4 months after the 3-dose vaccination series)

Number of subjects reporting any solicited local or systemic Adverse Events (AEs)

Timeframe: Day 1 (6 hours) to Day 7 after vaccination

Number of subjects reporting any unsolicited AEs

Timeframe: Day 1 to Day 30 after any vaccination

Number of subjects reporting any serious adverse events (SAEs), medically-attended AEs and AEs leading to premature withdrawal.

Timeframe: During the entire study period (from Day 0 up to Month 10)

Interventions:
Biological/vaccine: Meningococcal ABCWY
Biological/vaccine: Placebo
Enrollment:
189
Observational study model:
Not applicable
Primary completion date:
2015-26-03
Time perspective:
Not applicable
Clinical publications:
Welsch A et al. (2018) Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study. Vaccine.. 36(35):5309-5317.
Medical condition
Meningococcal disease
Product
GSK3536819A
Collaborators
Not applicable
Study date(s)
December 2014 to June 2015
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
10 - 19 years
Accepts healthy volunteers
No
  • Adolescents who completed V102_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo).
  • Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis.
  • History of any meningococcal vaccine administration other than vaccination given in the parent V102_16 protocol.
Inclusion and exclusion criteria
Inclusion criteria:
  • Adolescents who completed V102_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo).
Exclusion criteria:
  • Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis.
  • History of any meningococcal vaccine administration other than vaccination given in the parent V102_16 protocol.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Cleveland, Ohio, United States, 44121
Status
Study Complete
Contact us
Location
GSK Investigational Site
Huntsville, Alabama, United States, 35802
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
Status
Study Complete
Contact us
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40207
Status
Study Complete
Contact us
Location
GSK Investigational Site
Melbourne, Florida, United States, 32934
Status
Study Complete
Contact us
Location
GSK Investigational Site
Newton, Kansas, United States, 67114
Status
Study Complete
Contact us
Location
GSK Investigational Site
Omaha, Nebraska, United States, 68134
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wichita, Kansas, United States, 67207
Status
Study Complete
Contact us

Study documents

Study report synopsis
Available language(s): English
Download document(s)
Protocol
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Completed
Actual primary completion date
2015-26-03
Actual study completion date
2015-11-06

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website